ESR1 and neoplasm: Triple-negative breast cancer (TNBC), a very aggressive subtype of BC that accounts for 15–20% of breast cancer cases, has limited access to targeted therapy because of the lack of hormone receptors (ER and PR) and HER2 expression [2] in the tumor cells.